BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 26773096)

  • 21. ST-Producing E. coli Oppose Carcinogen-Induced Colorectal Tumorigenesis in Mice.
    Li P; Lin JE; Snook AE; Waldman SA
    Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28895923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
    Castro J; Harrington AM; Hughes PA; Martin CM; Ge P; Shea CM; Jin H; Jacobson S; Hannig G; Mann E; Cohen MB; MacDougall JE; Lavins BJ; Kurtz CB; Silos-Santiago I; Johnston JM; Currie MG; Blackshaw LA; Brierley SM
    Gastroenterology; 2013 Dec; 145(6):1334-46.e1-11. PubMed ID: 23958540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GUCY2C ligand replacement to prevent colorectal cancer.
    Blomain ES; Pattison AM; Waldman SA
    Cancer Biol Ther; 2016 Jul; 17(7):713-8. PubMed ID: 27104761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of guanylin and GC-C in rat mesenteric macrophages in resistance to a high-fat diet.
    Akieda-Asai S; Sugiyama M; Miyazawa T; Koda S; Okano I; Senba K; Poleni PE; Hizukuri Y; Okamoto A; Yamahara K; Mutoh E; Aoyama F; Sawaguchi A; Furuya M; Miyazato M; Kangawa K; Date Y
    J Lipid Res; 2013 Jan; 54(1):85-96. PubMed ID: 23081987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia.
    Bashir B; Merlino DJ; Rappaport JA; Gnass E; Palazzo JP; Feng Y; Fearon ER; Snook AE; Waldman SA
    Hum Pathol; 2019 May; 87():103-114. PubMed ID: 30716341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins.
    Pattison AM; Blomain ES; Merlino DJ; Wang F; Crissey MA; Kraft CL; Rappaport JA; Snook AE; Lynch JP; Waldman SA
    Infect Immun; 2016 Oct; 84(10):3083-91. PubMed ID: 27481254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.
    Rappaport JA; Waldman SA
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1125-1137. PubMed ID: 32945718
    [No Abstract]   [Full Text] [Related]  

  • 28. Silencing the intestinal GUCY2C tumor suppressor axis requires
    Pattison AM; Barton JR; Entezari AA; Zalewski A; Rappaport JA; Snook AE; Waldman SA
    Cancer Biol Ther; 2020 Sep; 21(9):799-805. PubMed ID: 32594830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia.
    Rappaport JA; Waldman SA
    Front Oncol; 2018; 8():299. PubMed ID: 30131940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guanylin and uroguanylin induce natriuresis in mice lacking guanylyl cyclase-C receptor.
    Carrithers SL; Ott CE; Hill MJ; Johnson BR; Cai W; Chang JJ; Shah RG; Sun C; Mann EA; Fonteles MC; Forte LR; Jackson BA; Giannella RA; Greenberg RN
    Kidney Int; 2004 Jan; 65(1):40-53. PubMed ID: 14675035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A β-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer.
    Rappaport JA; Entezari AA; Caspi A; Caksa S; Jhaveri AV; Stanek TJ; Ertel A; Kupper J; Fortina PM; McMahon SB; Jaynes JB; Snook AE; Waldman SA
    Cell Mol Gastroenterol Hepatol; 2022; 13(4):1276-1296. PubMed ID: 34954189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uroguanylin: how the gut got another satiety hormone.
    Seeley RJ; Tschöp MH
    J Clin Invest; 2011 Sep; 121(9):3384-6. PubMed ID: 21865649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Differential expression of guanylin in colorectal cancer].
    Chen YB; Zhu YP; Feng HY; Liu Y; Qian J; Fan YT; Li DC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Sep; 12(5):515-7. PubMed ID: 19742348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guanylin and uroguanylin stimulate lipolysis in human visceral adipocytes.
    Rodríguez A; Gómez-Ambrosi J; Catalán V; Ezquerro S; Méndez-Giménez L; Becerril S; Ibáñez P; Vila N; Margall MA; Moncada R; Valentí V; Silva C; Salvador J; Frühbeck G
    Int J Obes (Lond); 2016 Sep; 40(9):1405-15. PubMed ID: 27108812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers.
    Weinberg DS; Foster NR; Della'Zanna G; McMurray RP; Kraft WK; Pallotto A; Kastenberg DM; Katz LC; Henry CH; Moleski SM; Limburg PJ; Waldman SA
    Cancer Biol Ther; 2021 Dec; 22(10-12):544-553. PubMed ID: 34632925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.
    Witek M; Blomain ES; Magee MS; Xiang B; Waldman SA; Snook AE
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1188-95. PubMed ID: 24661671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guanylate cyclase C deficiency causes severe inflammation in a murine model of spontaneous colitis.
    Harmel-Laws E; Mann EA; Cohen MB; Steinbrecher KA
    PLoS One; 2013; 8(11):e79180. PubMed ID: 24244444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GUCY2C-targeted cancer immunotherapy: past, present and future.
    Snook AE; Magee MS; Waldman SA
    Immunol Res; 2011 Dec; 51(2-3):161-9. PubMed ID: 22038530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases.
    Jarmuż A; Zielińska M; Storr M; Fichna J
    Neurogastroenterol Motil; 2015 Aug; 27(8):1057-68. PubMed ID: 25930667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absence of Receptor Guanylyl Cyclase C Enhances Ileal Damage and Reduces Cytokine and Antimicrobial Peptide Production during Oral Salmonella enterica Serovar Typhimurium Infection.
    Majumdar S; Mishra V; Nandi S; Abdullah M; Barman A; Raghavan A; Nandi D; Visweswariah SS
    Infect Immun; 2018 May; 86(5):. PubMed ID: 29463616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.